Table 1.
Baseline characteristics.
| Variable | All Patients (n = 25) |
|---|---|
| Age at diagnosis, years | 54 (51–55) |
| Age at LuPSMA-RLT initiation, years | 62 (57–71) |
| Time to CR, years | 4.5 (1.3–13.8) |
| Time to LuPSMA-RLT initiation after diagnosis, years | 8.3 (4–13.9) |
| Gleason score *: | |
| <8 | 8 (38) |
| ≥8 | 13 (62) |
| PSA at LuPSMA-RLT initiation (ng/mL) | 179 (69.5–1142) |
| PSA Doubling Time, months | 2 (1.2–3.4) |
| Hemoglobin (g/dL) | 11 (9.5–11.9) |
| White blood cells (109/L) | 6.2 (5.1–7.2) |
| Platelets (109/L) | 276 (217–335) |
| eGFR (mL/min/1.73 m2) | 95.3 (72.5–103.8) |
| Alkaline phosphatase (U/L) | 235 (124–568.5) |
| Lactate dehydrogenase (U/L) | 315 (268–509.5) |
| Disease involvement: | |
| Bone metastases | 24 (96) |
| Lymph node metastases | 20 (80) |
| Visceral metastases | 11 (44) |
| hepatic | 7 (28) |
| pulmonary | 4 (16) |
| Primary | 6 (24) |
| VAS: | |
| <4 | 11 (44) |
| ≥4 | 14 (56) |
| ECOG performance status: | |
| <2 | 8 (32) |
| ≥2 | 17 (68) |
| Previous treatment: | |
| Abiraterone | 24 (96) |
| Enzalutamide | 18 (72) |
| 223Radium dichloride | 5 (20) |
| Docetaxel | 25 (100) |
| Cabazitaxel | 15 (60) |
| Nontaxane chemotherapy ** | 4 (16) |
Data presented as median with interquartile range (IQR), or n (%), LuPSMA RLT: 177Lutetium-PSMA-617 radioligand therapy, CR: castration resistance, PSA: prostate-specific antigen, eGFR: estimated glomerular filtration rate, VAS: Visual Analogue Score, ECOG: Eastern Cooperative Oncology Group, *: for available patients (n = 21), ** including one or more regimens: cisplatin, etoposide, 5-FU, carboplatin AUC 5, oxaliplatin, capecitabine, mitoxantrone.